Table 3 Non-exhaustive selection of studies culturing vibrating microtome-generated slices from different tumor types
From: Culture of vibrating microtome tissue slices as a 3D model in biomedical research
Tumor type | Species | Slice thickness | Culture time (max) | Culture system features | Purpose | Ref |
|---|---|---|---|---|---|---|
Lung | hu | 300 µm | 6 months | Implanted into mice (xenograft) | Model for primary tumor expansion and xenograft production | [69] |
sh, ms | 300 µm | 1 month | Submerged | Standardized slice model for viral infection gene therapy | [70] | |
ms | 160-250 µm | 3 days | ALI, titanium grid, rotation | Tumor drug testing model | [71] | |
Oral squamous cell carcinoma | hu | 350–450 µm | 8 days | Chorioallantoic membrane (CAM) | Establishing slices on CAM as a tumor model | [72] |
Gastrointestinal (various) | hu | 250 µm | 7 days | On insert, submerged | Protocol, method evaluation | [73] |
Prostate | hu | 200-300 µm | 10 days | Submerged, hypoxia | Prostate tumor model | [59] |
ms | 300 µm | 6 days | With/without insert and strainer | Establishing a chemotherapy model | [74] | |
hu | 250 µm | 9 days | On insert, ALI | Model for immune microenvironment studies | [75] | |
hu | 350 µm | 96 h | On insert, submerged | Model development | [76] | |
hu | 350 µm | 96 h | On insert, submerged | Assessing culture effects by transcriptome profiling | [77] | |
hu | 250 µm | 9 days | On insert, ALI | Model development | [78] | |
hu | 250 µm | 4 days | On insert, ALI | Tumor immunology studies | [79] | |
hu | 300 µm | 15 days | On insert, ALI | Method development | [80] | |
hu | 250 µm | 6 days | On insert, submerged | Interaction of tumor cells with immune microenvironment | [81] | |
Liver | hu | 200-300 µm | 3 days | Submerged | Comparison of slicing devices | [82] |
hu, ms | 200-300 µm | 7 days | On insert, submerged | Drug discovery, immuno-oncology | [83] | |
hu | 250 µm | 4 days | On insert, submerged | Immune checkpoint ligands and chemotherapy response | [84] | |
hu | 250 µm | 6 days | On insert, submerged | Establish CarT-cell treatment model | [85] | |
hu | 250 µm | 3 days | On insert, submerged | Neutralizing antibodies and CAR-T cells in cancer therapy | [86] | |
Bladder | hu | 300 µm | 2 days | On insert, submerged, on a rotating plate | Method for studying oncolytic viruses | [87] |
Kidney | hu | 300 µm | 1 week | Submerged | Characterization of the tumor immune environment | [88] |
Uterine leiomyoma | hu | 500 µm | 3 weeks | On alginate scaffold discs | Model development | [89] |
Breast | hu | 300 µm | 7 days | Submerged with/without rotating platform | Model development, comparison with manual slicing | [90] |
hu | 250 µm | 7 days | Submerged | Model evaluation | [91] | |
hu | 250 µm | 3 days | Submerged | Establishing a chemotherapy model | [92] | |
Breast (xenograft) | hu | 200 µm | 4 days | Submerged | Drug testing | [93] |
Breast and prostate PDX models | hu | 300 µm | 2 weeks (breast), 1 week (prostate) | In chip, submerged, shear stress, perfusion | Cancer on chip platform for predicting drug response | [94] |
Head and Neck Squamous Cell Carcinoma | hu | 300 µm | 5 days | Rotating platform | Model for evaluation of treatment response to radiation and chemotherapy | [95] |